Dapagliflozin/sitagliptin explained
| Type: | combo |
| Component1: | Dapagliflozin |
| Class1: | SGLT-2 inhibitor |
| Component2: | Sitagliptin |
| Class2: | DPP-4 inhibitor |
| Tradename: | Sidapvia |
| Pregnancy Au: | D |
| Routes Of Administration: | By mouth |
| Atc Prefix: | A10 |
| Atc Suffix: | BD29 |
| Legal Au: | S4 |
| Legal Au Comment: | [1] [2] [3] |
| Legal Status: | KR: Rx-only[4] |
Dapagliflozin/sitagliptin, sold under the brand name Sidapvia, is a fixed-dose combination anti-diabetic medication used for the treatment of type 2 diabetes. It contains dapagliflozin, as propanediol monohydrate, a SGLT-2 inhibitor; and sitagliptin, as phosphate monohydrate, a DPP-4 inhibitor. It is taken by mouth.
Notes and References
- Web site: TGA eBS - Product and Consumer Medicine Information Licence . 8 July 2024 . 8 July 2024 . https://web.archive.org/web/20240708153343/https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent=&id=CP-2024-PI-02050-1 . live .
- Web site: Sidapvia (AstraZeneca Pty Ltd) . Therapeutic Goods Administration (TGA) . 1 July 2024 . 8 July 2024 . 7 July 2024 . https://web.archive.org/web/20240707062738/https://www.tga.gov.au/resources/prescription-medicines-registrations/sidapvia-astrazeneca-pty-ltd . live .
- Web site: Sidapvia 10/100 dapagliflozin 10 mg (as propanediol monohydrate)/sitagliptin 100 mg (as phosphate monohydrate) film coated tablets blister pack (405540) . Therapeutic Goods Administration (TGA) . 8 June 2024 . 8 July 2024 . 8 July 2024 . https://web.archive.org/web/20240708153356/https://www.tga.gov.au/resources/artg/405540 . live .
- Web site: Dunleavy K . AstraZeneca enlists SK Chemicals to produce diabetes combo drug Sidapvia . Fierce Pharma . 24 July 2023 . 8 July 2024.
